Home About Us Research & Development Investors & Media Careers Contact Us

News Highlights

July 8, 2014
Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499; Provides Direction for Phase 3 Development in Diabetic Nephropathy

May 14, 2014
Concert Pharmaceuticals Reports First Quarter 2014 Financial Results

April 25, 2014
Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 Clinical Trial of CTP-499 in Diabetic Kidney Disease



Welcome to Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company. We apply our extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs.

MedChem News
Deuterium Medicinal Chemistry: A New Approach to Drug Discovery and Development Read more

Issued U.S. Patents

Concert is building a broad patent estate. View List


Concert has presented at a number scientific meetings. View Poster presentations

  ©2009 Concert Pharmaceuticals, Inc.
Design by Digizyme
Home     Sitemap